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Abstract: 
Introduction: As in obstructive sleep apnea (OSA), the chronic cycles of hypoxia and 
reoxygenation are thought to be conducive of oxidative stress (OS) with generation of reactive 
oxygen species, identifying effective mechanisms of protection against oxidant-mediated tissue 
damage becomes of outmost importance. Leptin’s role had been recently extended into that of 
participant to OS; while its exact role in this process is yet to be defined, elevated leptin levels 
correlate significantly with several indices of OSA disease severity such as nocturnal hypoxemia, 
possibly acting as a counteractive mechanism against the chronic intermittent hypoxia-related 
OS and serving as a marker of future risk of atherosclerotic disease. We therefore investigated 
leptin’s antioxidant mechanism on superoxide (O 2 −• ) anions using spectrophotometry and 
electron paramagnetic resonance (EPR). 
Methods: The O 2 −• was generated by oxidation of xanthine (XAN) by xanthine oxidase (XO) in 
the presence of spin trap 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide with various 
concentrations of leptin (0.001, 0.01, 0.1, and 1 mg/ml) and without leptin. Signal intensity 
between 3,440 and 3,540 G was expressed as standard means ± SD. The activity of leptin on XO 
was determined by monitoring the conversion of XAN to uric acid at 293 nm using a Beckman 
DU 800 UV–visible spectrophotometer. 
Results: Leptin added to aqueous solutions at 0.1 and 1 mg/ml concentrations was associated 
with a statistically significant decrease in the EPR signal due to leptin’s direct scavenging 
activity towards the O 2 −• . 
Conclusion: Leptin is an antioxidant agent of possible use as a marker of OS and future risk of 
atherosclerotic disease in OSA. 
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Article: 
Introduction 
Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive collapse of the 
pharyngeal airway during sleep resulting in a myriad of adverse vascular risks from insulin 
resistance to dyslipidemia, elevated diastolic blood pressure, and leptin levels. The mechanism of 
action by which hyperleptinemia is present in adults with OSA [1] is likely multifactorial; these 
patients have central or peripheral (receptor and post receptor) [2] leptin resistance with 
subsequently high circulating leptin levels, possibly related to an enhanced sympathetic drive 
due to hypoxia [3, 4]. Another plausible explanation could be that leptin acts as a counter effect 
to hypoventilation [5, 6], as studies have also demonstrated that leptin levels fall subsequently to 
continuous positive airway pressure (CPAP) therapy [7, 8]. Recent evidence revealed the 
multifaceted properties of leptin, a 167-amino acid protein with a structure similar to cytokines 
and secreted predominantly by the adipocyte cells. Initially discovered as a hormone that 
regulated food intake and energy balance [9], it subsequently proved as having important roles in 
hypoxia such as inducer of angiogenesis [10] and promoter of the hypoxia-inducible gene [11]. 
As in OSA, the chronic cycles of hypoxia and reoxygenation [12] are thought to be conducive of 
oxidative stress (OS) and generation of reactive oxygen species (ROS) [13] by a pathologic 
mechanism similar to that of ischemia–reperfusion, identifying effective mechanisms of 
protection against oxidant-mediated tissue damage becomes of outmost importance especially for 
severe disease due to reduced values of antioxidant capacity [14]. 
Recently, leptin’s role had been extended into that of participant to OS by upregulating transcript 
levels of superoxide dismutase (SOD) 1, glutathione peroxidase, and glutathione S-transferase in 
ob/ob mice [15] and stimulation of the mRNA expression of SOD 2 in the serum-deprived 
cardiomyocytes [16, 17]. Given leptin’s strong correlation with the degree of obesity [18] and 
implicitly obesity-induced, inflammation-related OS [19], its exact role in this process is yet to 
be defined. However, as case–control studies have demonstrated increased serum leptin in OSA, 
despite similar levels of obesity [20], and these levels have correlated significantly with the 
degree of nocturnal hypoxemia independent of the degree of obesity in these patients 
[14, 21, 22], we thought to further assess leptin’s ability and mechanism as a counteractive agent 
[23] against chronic intermittent hypoxia (CIH)-related OS. 
Oxidative stress is defined as the imbalanced redox state in which prooxidants overwhelm the 
antioxidant capacity, resulting in an increased production of ROS, ultimately leading to oxidative 
damage of cellular macromolecules [15]. Perhaps the most important ROS, given its long half 
life and ability to move to locations where it can undergo interactions with other molecules, is 
superoxide anion radical (O 2 −• ) [24]; its corresponding antioxidant defense includes direct-
acting enzymes, such as SOD and catalase, and supporting enzymes, such as xanthine oxidase 
(XO). The univalent reduction of molecular oxygen by XO action on xanthine 
(XAN)/hypoxanthine generating O 2 −• is known to play an important role in the oxidative tissue 
injury process. Activation of XO, which in turn may produce increased amounts of O 2 −• , may 
result in the disruption of the macromolecules by acting both directly and/or indirectly via the 
formation of secondary oxidants [25]. The therapeutic effects derived from the inhibition of 
XO/O 2 −• have been successfully demonstrated for gout, tumor lysis syndrome, cardiovascular 
disease, stroke, and diabetes. On the other hand, studies looking for a similar therapeutic effect in 
the lungs have been extremely few [26] without conclusive results. In OSA disease, however, an 
important role of XO had been detailed by demonstrating that allopurinol, an XO inhibitor, 
reduced the level of OS as quantified by malonaldehyde, an oxidative damage marker, probably 
by decreasing free radical generation through inhibition of the XO system [12]. Therefore, due to 
the proven clinical efficacy of decreasing systemic OS through the XO system and the known 
leptin safe profile [27] and convenience of the intranasal route administration [28], we 
hypothesized that one of leptin’s protective mechanisms against hypoxia/reoxygenation with 
ROS formation is due to its ability to inhibit XO and subsequently O 2 −• formation and we tested 
this hypothesis using spectrophotometry and electron paramagnetic resonance (EPR) 
spectroscopy in combination with spin trapping, the most sensitive and specific technique of 
detecting free radicals. 
Materials and methods 
Chemicals and materials 
Purified 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline N-oxide (DEPMPO) was purchased from 
Alexis (Carlsbad, CA, USA). Leptin, XAN, XO, and all other chemicals and reagents were 
obtained from Sigma Chemicals (St. Louis, MO, USA). 
EPR study of the scavenging activity of leptin towards O 2 −• 
EPR is an excellent approach for the detection of radicals [14]. The O 2 −• was generated by 
oxidation of XAN by XO in the presence of spin trap DEPMPO and with or without leptin as 
previously described with slight modifications [29]. 
Briefly, the reaction mixture in phosphate buffered saline (PBS) contained 36 μM XAN, 
32 mU/ml XO, and 10 mM DEPMPO in the absence (control samples) or presence of various 
concentrations of leptin (0.001, 0.01, 0.1, and 1 mg/ml) in a final volume of 0.1 ml in a test tube. 
After 10 min of reaction, the reaction mixture was then transferred to a capillary tube for EPR 
spectral analysis. EPR spectra were recorded at room temperature using a spectrometer (Bruker 
D-200 ER, IBM Bruker), operating at the X-band with a TM cavity and capillary tube. The EPR 
spectrometer settings were modulation frequency, 100 KHz; X-band microwave frequency, 
9.5 GHz; microwave power, 20 mW; modulation amplitude, 6.3 G; time constant, 160 s; scan 
time, 200 s; and receiver gain, 4 × l05. The effect was estimated by the percent age of variation in 
the EPR signal intensity of the DEMPO–O 2 −• adduct compared with that of the controls without 
leptin (representing 100%). 
Measurement of uric acid formation by xanthine oxidase reaction 
The activity of XO was determined by monitoring the conversion of XAN to uric acid at 293 nm 
using a Beckman DU 800 UV–visible spectrophotometer. The reaction mixture contained 1.0 ml 
of 50 mM PBS, pH 7.4, 0.1 mM DTPA, 36 μM XAN, and 32 mU/ml XO in the absence or 
presence of various concentrations of leptin (0.001, 0.01, 0.1, and 1 mg/ml). The reaction 
mixture was incubated for 5 min at 37°C prior to measurement of uric acid production at 293 nm 
and prior to the addition of XO to start the reaction. 
Statistical analysis 
The EPR signal intensity (n = 8) between 3,440 and 3,540 G was reported as standard means ± 
SD. The Mann–Whitney test was used for identifying the effect of various leptin concentrations 
(0.001, 0.01, 0.1, and 1 mg/ml) on O 2 −• and uric acid formation by the XAN/XO system as 
compared with the control. Results were reported as p value and confidence interval; p < 0.05 
was considered statistically significant. 
Results 
In order to confirm the precise O 2 −• scavenging activity, a steady-state enzymatic XAN/XO 
system was used. At all final concentrations, leptin added to the aqueous solution resulted in a 
decrease in EPR signal that was concentration dependent. The EPR signal intensities of leptin-
containing solutions compared with controls were as follows: 85 ± 23% for the low concentration 
leptin solution (LL, i.e., 0.001 mg/ml); 83 ± 23% for the intermediate concentration leptin 
solution (IL, i.e., 0.01 mg/ml); 71 ± 17% for the high concentration leptin solution (HL, i.e., 
0.1 mg/ml); and 50 ± 14% for the very high leptin concentration solution (VHL, i.e., 1 mg/ml). 
As shown in Fig. 1, the intensity of the signal decreased, from top (control) to bottom (VHL), 
with increasing leptin concentrations of 0.001 mg/ml (Fig. 1, LL), 0.01 mg/ml (Fig. 1, IL), 
0.1 mg/ml (Fig. 1, HL), and 1 mg/ml (Fig. 1, VHL). Compared with controls, leptin in both HL 
(p = 0.0003, CI 15.7–41.79) and VHL (p < 0.0001, CI 39.38–60.62) solutions was found to 
inhibit the O 2 −• statistically significantly (Fig. 2). 
 
Fig. 1 EPR spectroscopy in combination with the spin probe DEPMPO was used to examine the 
superoxide-scavenging capability of leptin. From top to bottom: NL (no leptin) or control; LL, 
i.e., 0.001 mg/ml leptin concentration; IL, i.e., 0.01 mg/ml leptin concentration; HL, i.e., 
0.1 mg/ml leptin concentration; and VHL, 1 mg/ml leptin concentration 
 
Fig. 2 Scavenging of the superoxide anion by leptin. Effect of leptin concentrations on the EPR 
signal corresponding to the O 2 −• adduct with DEPMPO. The 100% reference value corresponds 
to the level of the DEPMPO–O 2 -• adduct produced in the corresponding control sample without 
leptin. NL no leptin; LL low leptin concentration solution, i.e., 0.001 mg/ml; IL intermediate 
leptin concentration solution, i.e., 0.01 mg/ml; HL high leptin concentration solution, i.e., 
0.1 mg/ml; and VHL very high leptin concentration solution, i.e., 1 mg/ml. Mann–Whitney test 
for each treatment showed differences (p < 0.05); asterisk, significant differences compared to 
control 
At all final concentrations (0.001, 0.01, 0.1, and 1 mg/ml), leptin failed to inhibit uric acid 
formation by the XAN/XO system as compared with control (Fig. 3), indicating that leptin does 
not inhibit XO, the source of O2 −• production. Therefore, the decrease in EPR signal was due to 
leptin’s direct effect on the O 2 −• . 
 
Fig. 3 The effects of leptin on the formation of uric acid by the xanthine/xanthine oxidase 
system. The reaction mixture contained 36 μM xanthine and 32 mU/ml xanthine oxidase in PBS. 
Indicated various concentrations of leptin were added to the reaction mixture. After incubation 
for 5 min at 37°C, the formation of uric acid was measured at 293 nm 
Discussion 
Our results demonstrate that leptin added to aqueous solutions at 0.1 and 1 mg/ml concentrations 
was associated with a statistically significant decrease in the EPR signal due to leptin’s direct 
scavenging activity towards the O 2 −• , the highest scavenging activity being seen at the final 
concentration of 1 mg/ml. 
The formation of toxic-free oxygen radicals, such as O 2 −• , has been implicated in several major 
disease processes, both of acute (post-hypoxic neuronal damage [9], sepsis, and acute lung injury 
[30]) and chronic pathology (atherosclerosis [31], immunity [32], and ischemic and myopathic 
heart disease [33]). In OSA disease, the increased ROS [34] due to intermittent 
hypoxia/reoxygenation phenomenon are thought to participate to the endothelial damage, linking 
the OS to the important concept of future risk of atherosclerotic disease; several markers of such 
processes, including O 2 −• [35], hydrogen peroxide [36], nitric oxide [37], and ROS in CD11c 
monocytes [38], have been found to be altered in this disease and restored subsequent to CPAP 
therapy. 
While our study is the first to specifically address a potential role of leptin in the OSA-associated 
redox balance, mounting general evidence supports our findings, reporting antioxidant properties 
of leptin in several other non-OSA conditions. Patients with leptin gene mutation had defective 
antioxidant defense as evidenced by reduced levels of glutathione peroxidase (GSH-P) and 
erythrocyte copper–zinc superoxide dismutase [23]. In vitro, leptin resulted in SOD activation in 
the ob/ob mice [15] and primary cultured cardiomyocytes [16], and in vivo, leptin acted as a 
powerful antioxidant in the rat bladder after ischemia–reperfusion injury [39]. The above 
findings, along with reports of leptin administration to the leptin-deficient ob/ob mouse resulting 
in the rebuild of the antioxidant enzymes catalase, GSH-P, and GSH-R [30], bring into question 
the potential research and clinical role of leptin as an antioxidant agent by mechanisms yet to be 
defined. 
Few of the studies with focus on leptin and its oxidant/antioxidant properties contradict our 
results; in these studies, leptin administration to the non-HIV human monocytes, heart 
endothelial cells, and rat hepatic stellate cells resulted in stimulation of the oxidative burst and 
ROS production [40–42]. However, in none of these studies, the antioxidant response had been 
quantified and therefore we consider that a rather beneficial effect of leptin could have been 
missed due to lack of evidence of the increased antioxidant component in excess to that of ROS 
production, leading to an overall improved redox balance [30]. 
To the best of our knowledge, this is the first study to evaluate leptin's scavenging properties on 
O 2 −• using the EPR spin trapping method, establishing evidence towards its antioxidant 
mechanisms and weighing the clinical value of these new findings in the context of OSA disease. 
The main weakness of our study is related to concentrating our efforts on using a high 
concentration of leptin solution. As the few available studies on leptin's protective role against 
OS report contradicting results for the low or moderate concentration solutions [17, 43, 44], we 
instead opted for using high and very high leptin concentration solutions given current evidence 
reporting leptin administration by intranasal or peripheral route as being safe [27] and efficient 
[45, 46]. We also opted on studying a single ROS, the O 2 −• , due to (1) its involvement in 
oxygenation–reoxygenation phenomenon, such as seen in CIH induced by OSA [47]; (2) known 
interaction with nitric oxide radicals yielding peroxynitrite, another major ROS; and (3) previous 
evidence demonstrating potent O 2 −• scavengers (i.e., manganese (III) tetrakis (1-methyl-4-
pyridyl) porphyrin pentachloride) being successful in preventing the intermittent hypoxia-evoked 
changes in the cardiorespiratory system as well as gene expression [48]. 
Our study has several strengths: first, it benefited from the use of the EPR spin trapping method 
[49], a very accurate and elegant method for the detection of radicals. Second, it looked into 
detailing a possible antioxidant pathway for leptin, rather than evidencing its endpoint properties 
only as antioxidant for O 2 −• . Lastly, it expanded the important concept of OSA-related redox 
balance into clinical significance by eloquently demonstrating leptin's properties as antioxidant 
and marker of OS. 
In conclusion, our study establishes evidence towards leptin's potential as an antioxidant agent 
and suggests its possible clinical significance as a marker of OS and future risk of atherosclerotic 
disease in OSA. 
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